[NMusers] Re: NONMEM 7.1.2 run time in Windows 7

2011-03-11 Thread Santosh
We noticed that gfortran installed on Windows 7 and Linux workstations are 32-bit and 64-bit, respectively. Are there ways to install 64-bit gfortran on Windows 7? Regards, Santosh On Thu, Mar 10, 2011 at 9:42 AM, Santosh wrote: > I forgot to mention.. > > Fortran compiler: gfortran 4.5.0 > Th

Re: RE: [NMusers] PK and PD variability

2011-03-11 Thread alindauer-research
Jean, I don't have previous PK/PD data, only PK. Joseph, thanks for your interesting suggestion. Unfortunatly, I will be out of the office for a week, so I can't check it right now. I'll get back with the results. Regards, Andreas. 

RE: [NMusers] PK and PD variability

2011-03-11 Thread Lavigne, Jean
Dear Andreas, Perhaps one strategy would be to use the data from the previous PK/PD study and to first fit the PK data. Then fit your nice Emax model based on the PK model . You could fit simultaneously the PK/PD from the previous study. From this point you have several path you can take to

[NMusers] unsubscribe

2011-03-11 Thread Pete Stagg

RE: [NMusers] PK and PD variability

2011-03-11 Thread alindauer-research
Joseph, with adding IIV on dose I meant multiplying DOSE in the Emax model with a bioavailability parameter F with its theta fixed to 1 and omega fixed to 55% CV: E.g.: IPRED = BL + EMAX * F*DOSE/(ED50+F*DOSE) where F = theta(F)*exp(eta(F)) Sorry for not being clear. Regards, Andreas. Andr

RE: [NMusers] PK and PD variability

2011-03-11 Thread Standing Joseph (GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS TRUST)
Dear Andreas, When you say you add IIV on dose, I'm not sure exactly what you mean but suggest you need to take a 2 step approach. In order to replicate variability in dose, you will need to simulate doses with variability, and then in a second step use these simulated doses to estimate the Em

[NMusers] PK and PD variability

2011-03-11 Thread alindauer-research
Dear group, I am currently analyzing some dose-response data for one of our drugs. A simple Emax model nicely described the dose-response relationship for the principal PD variable (a continuous measure). Unfortunately, no PK data was obtained from the subjects in the PD study. Since the variab